Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/268771 
Year of Publication: 
2023
Series/Report no.: 
SWP Comment No. 2/2023
Publisher: 
Stiftung Wissenschaft und Politik (SWP), Berlin
Abstract: 
The COVID-19 pandemic and war in Ukraine have highlighted the dependence of the European Union (EU) on individual trading partners. One of the tasks of the European Commission's new Directorate-General, the Health Emergency Preparedness and Response Authority (HERA), established in 2021, will therefore be to contribute to the EU's 'open strategic autonomy' by identifying and eliminating import dependencies in the field of pharmaceuticals. HERA's work thus aligns with current EU efforts to reduce concentrated import risks. Here, three aspects of this work are particularly important: the identification of dependencies, the development of strategies to overcome them and the incorporation of these strategies within global health governance.
Subjects: 
Health Emergency Preparedness and Response Authority
HERA
Biomedical Advanced Research and Development Authority
BARDA
Critical Raw Materials Act
CRMA
European Raw Materials Alliance
ERMA
European Chips Act
Global Antibiotic Research & Development Partnership
GARDP
Innovative Health Initiative
IHI
Incubator for Antibacterial Therapies in Europe
INCATE
Minerals Security Partnership
MSP
Raw Materials Investment Platform
RMIP
Covid-19
NextGenerationEU
rescEU
UN Comtrade
European Centre for Disease Prevention and Control
ECDC
Important Project of Common European Interest
IPCEI
pharmaceuticals
antibiotics
Active Pharmaceutical Ingredients
API
Finished Pharmaceutical Product
FPP
supply chains
global health governance
Reshoring
friend-shoring
Persistent Identifier of the first edition: 
Document Type: 
Research Report

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.